Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.

Abstract:

:Peripheral blood progenitor cell (PBPC) populations used for transplantation were analyzed for the presence of CD34+ cells, colony-forming cells (initial CFC), and long-term culture initiating cells (LTC-IC) cultured on irradiated stroma for 5 weeks. Thirty-eight leukapheresis products were studied from 11 patients with breast cancer, 2 with non-Hodgkin's lymphoma and 1 with ovarian cancer harvested during recovery from either cyclophosphamide (CY) chemotherapy or cyclophosphamide-VP16 with G-CSF (CY-VP-G). CY-VP-G products had a threefold higher median number of mononuclear cells collected, a fivefold higher median concentration of CD34 and LTC-IC and a threefold higher concentration of initial-CFC when compared with CY products. CY-VP-G products had a significantly higher ratio of CFU-GM to BFU-E than the CY-mobilized products. Significant correlations of r = 0.89 and r = 0.68 were observed when comparing CD34 and CFC in products from CY or CY-VP-G patients, respectively. Analysis of the regression lines indicated that slopes of these regression lines were significantly different with a ratio of CD34 to initial CFC of 15:1 in the CY-VP-G products versus 5.2:1 with the CY products. These data indicate a higher cloning efficiency of the CD34+ population in the products from CY-mobilized patients. Significant correlations of r = 0.9 (CY) and r = 0.53 (CY-VP-G) were observed when the initial CD34 concentration and the LTC-IC were compared. Comparison of initial CFC with LTC-IC also showed significant correlations (r = 0.94, CY; r = 0.58, CY-VP-G) in samples from both patient groups.(ABSTRACT TRUNCATED AT 250 WORDS)

journal_name

Bone Marrow Transplant

authors

Bender JG,Lum L,Unverzagt KL,Lee W,Van Epps D,George S,Coon J,Ghalie R,McLeod B,Kaizer H

subject

Has Abstract,Author List Incomplete

pub_date

1994-04-01 00:00:00

pages

479-85

issue

4

eissn

0268-3369

issn

1476-5365

journal_volume

13

pub_type

杂志文章
  • Relationship between clinical and BK virological response in patients with late hemorrhagic cystitis treated with cidofovir: a retrospective study from the European Group for Blood and Marrow Transplantation.

    abstract::To investigate the relationship between clinical response and modification of BK viremia, we assessed retrospectively 32 cases of hemorrhagic cystitis (HC) after allogeneic hematopoietic SCT that were treated with i.v. cidofovir (CDV). They were 22 men (69%) and 10 women (31%) with a median age of 24 years, range 3-62...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2012.247

    authors: Cesaro S,Pillon M,Tridello G,Aljurf M,Martino R,Schroyens W,Nozzoli C,Barba P,Faraci M,Fagioli F,Cappelli B,Cordonnier C,Al-Mohareb F,Floisand Y,Greil J,Panizzolo IS,Santarone S

    更新日期:2013-06-01 00:00:00

  • Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.

    abstract::A series of 22 consecutive pediatric patients undergoing ABMT for treatment of primary AML was reviewed in an efficacy analysis of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF). Treatment with at least two cycles of chemotherapy and a standard conditioning regimen of busulfan and cycloph...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Calderwood S,Doyle JJ,Hitzler JK,Saunders EF,Freedman MH

    更新日期:1996-07-01 00:00:00

  • Mesenchymal stem cells: heading into the clinic.

    abstract::In recent years, there has been an increasing interest in non-hematopoietic pluripotent progenitor cells that are found in the bone marrow. Mesenchymal stem cells (MSCs) are the first non-hematopoietic progenitors to be isolated from the bone marrow and extensively characterized. In addition to their ability to suppor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1702791

    authors: Koç ON,Lazarus HM

    更新日期:2001-02-01 00:00:00

  • Transient engraftment of T cell-depleted allogeneic bone marrow in mice improves survival rate following lethal irradiation.

    abstract::C3H/HeJ mice were exposed to 8 or 9 Gy total body irradiation prior to transplantation of 1-15 x 10(6) H-2 incompatible T cell-depleted bone marrow cells from C57BL/6 donors. Survival was greatly enhanced compared to irradiated controls, even at the lowest cell doses. Analysis of spleen cells 1-7 weeks post-transplant...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Lapidot T,Singer TS,Reisner Y

    更新日期:1988-03-01 00:00:00

  • Patient socioeconomic status as a prognostic factor for allo-SCT.

    abstract::The aim of the present study was to assess the influence of socioeconomic status (SeS) on the outcome of allo-SCT at a Brazilian SCT center. In total, 201 patients receiving HLA-identical related allo-SCTs were studied. The median age was 30 years. Overall, 163 patients had malignancies (CML 68, ALL/AML 63, myelodyspl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.358

    authors: Silla L,Fischer GB,Paz A,Daudt LE,Mitto I,Katz B,da Graça Grossini M,Bittencourt HN,Jochims A,Fogliatto L,Bittar CM,Friedrisch JR,Bittencourt RI

    更新日期:2009-04-01 00:00:00

  • Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.

    abstract::We report the response to the ABL kinase inhibitor imatinib mesylate (STI571) in a patient with chronic myeloid leukemia (CML) who relapsed twice after dose-reduced allogeneic stem cell transplantation (alloSCT) for B lymphoid blast crisis (BC) and failed to develop an antileukemic response despite grade 3 graft-versu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703885

    authors: Wassmann B,Scheuring U,Thiede C,Pfeifer H,Bornhäuser M,Griesinger F,Hochhaus A,Schleyer E,Gschaidmeier H,Hoelzer D,Ottmann OG

    更新日期:2003-04-01 00:00:00

  • Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis.

    abstract::Autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated as a therapy for patients with progressive multiple sclerosis (MS) at risk of debilitating neurological impairment. While preliminary results from a few studies have been reported, little is known about toxicities or outcome of HSCT...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703324

    authors: Oyama Y,Cohen B,Traynor A,Brush M,Rodriguez J,Burt RK

    更新日期:2002-01-01 00:00:00

  • Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future.

    abstract::beta-Thalassemia major and sickle cell disease (SCD) are among the most common hereditary disorders worldwide. The supportive treatment of beta-thalassemia major requires chronic, life-long RBC transfusions, which cause progressive iron overload and the potential for impaired endocrine, cardiac and hepatic function. T...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705943

    authors: Bhatia M,Walters MC

    更新日期:2008-01-01 00:00:00

  • Alternative donor SCT for the treatment of MHC class II deficiency.

    abstract::MHC Class II deficiency is a rare primary immunodeficiency disease characterized by absent HLA Class II expression resulting in CD4 lymphopenia, lack of Ag-specific responses and recurrent infection. Without successful allogeneic SCT, most children succumb to infection within the first decade of life. To date, alterna...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.140

    authors: Small TN,Qasim W,Friedrich W,Chiesa R,Bleesing JJ,Scurlock A,Veys P,Sparber-Sauer M

    更新日期:2013-02-01 00:00:00

  • Severe migratory polyarthritis following in vivo CAMPATH-1G.

    abstract::CAMPATH-1G is an IgG2b rat antihuman (CDw52) monoclonal antibody (MoAb) which is currently being used for T cell depletion in the setting of allogeneic bone marrow transplantation (BMT). In addition it elicits substantial lymphoid depletion, an effect which is being explored for remission induction in patients with ly...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Varadi G,Or R,Rund D,Orbach H,Slavin S,Nagler A

    更新日期:1995-12-01 00:00:00

  • Cytomegalovirus-specific immune recovery following allogeneic HLA-identical sibling transplantation with reduced-intensity preparative regimen.

    abstract::Cytomegalovirus (CMV) represents a major cause of morbidity after allogeneic stem cell transplantation (allo-SCT). Using interferon-gamma-enzyme-linked immunospot (ELISPOT) assay and HLA-peptide tetramers, we analysed 54 patients who received a reduced-intensity conditioning regimen, including fludarabine, busulphan a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704442

    authors: Mohty M,Mohty AM,Blaise D,Faucher C,Bilger K,Isnardon D,Sainty D,Gastaut JA,Viens P,Olive D,Gaugler B

    更新日期:2004-04-01 00:00:00

  • Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse.

    abstract::Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.217

    authors: Beck JC,Cao Q,Trotz B,Smith AR,Weigel BJ,Verneris MR,Burke MJ

    更新日期:2011-07-01 00:00:00

  • Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

    abstract::The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option. We evaluated the impact of ruxolitinib on the outcome after HCT....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.173

    authors: Jaekel N,Behre G,Behning A,Wickenhauser C,Lange T,Niederwieser D,Al-Ali HK

    更新日期:2014-02-01 00:00:00

  • The lung as a critical organ in marrow transplantation.

    abstract::Respiratory failure is the main cause of death in patients undergoing bone marrow transplantation (BMT). In this paper, clinical and research aspects as well as diagnostic, prophylactic and therapeutic strategies concerning the various forms of pulmonary and bronchial complications, which may evolve after BMT, are dis...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Quabeck K

    更新日期:1994-01-01 00:00:00

  • Risk of relapse in patients receiving azithromycin after allogeneic HSCT.

    abstract::Following publication of the ALLOZITHRO trial, the FDA released a safety announcement warning that azithromycin should not be given long-term to prevent BOS in patients with a blood or lymph cancer who have undergone allogeneic HSCT. Our site typically initiated azithromycin when patients were diagnosed with BOS post-...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01095-8

    authors: Kutzke JL,Merten JA,Taraba JL,Mara KC,Shah MV,Hashmi SK,Patnaik MM,Litzow MR,Hogan WJ,Alkhateeb HB

    更新日期:2020-10-31 00:00:00

  • Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy.

    abstract::We utilized mobilized peripheral blood stem cells (PBSC) as sole support for hematologic reconstitution following high-dose chemotherapy in 52 patients with advanced solid tumors and lymphoma. PBSC were collected by large scale leukapheresis after mobilization with chemotherapy. Each apheresis product was analysed for...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schwartzberg L,Birch R,Blanco R,Wittlin F,Muscato J,Tauer K,Hazelton B,West W

    更新日期:1993-05-01 00:00:00

  • Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

    abstract::Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2015.205

    authors: Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

    更新日期:2016-01-01 00:00:00

  • Mobilization of peripheral blood progenitor cells by high-dose Ara C, VP-16 and recombinant human granulocyte colony-stimulating factor: factors affecting progenitor cell yields.

    abstract::Forty seven patients with hematological malignancies were treated with high doses of cytosine arabinoside (Ara C; 12 g/m2) and etoposide (VP-16), followed by recombinant human granulocyte colony-stimulating factor (rhG-CSF; 50 micrograms/m2). Peripheral blood progenitor cells (PBPC) were collected during rapid leukocy...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Shimazaki C,Yamagata N,Tatsumi T,Hirata T,Oku N,Ashihara E,Goto H,Inaba T,Fujita N,Haruyama H

    更新日期:1995-05-01 00:00:00

  • Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters.

    abstract::Younger children are considered to be more vulnerable to late effects (LE), which prompted us to study LE in patients after haematopoietic stem cell transplantation (HSCT) for a haematological malignancy before the age of 3. In this multicentre EBMT study, cumulative incidence (CI) and severity of endocrine LE, centra...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/bmt.2016.139

    authors: Bresters D,Lawitschka A,Cugno C,Pötschger U,Dalissier A,Michel G,Vettenranta K,Sundin M,Al-Seraihy A,Faraci M,Sedlacek P,Versluys AB,Jenkins A,Lutz P,Gibson B,Leiper A,Diaz MA,Shaw PJ,Skinner R,O'Brien TA,Salooja

    更新日期:2016-11-01 00:00:00

  • Introduction: current issues in high-dose chemotherapy and stem cell support.

    abstract::In the 1980s it became clear that low numbers of primitive hematopoietic cells were present in the peripheral bloodstream. Early clinical trials by investigators in the USA, Australia, and Germany demonstrated that these cells could be collected and reinfused to support high-dose chemotherapy procedures in patients ot...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1701667

    authors: Shea TC

    更新日期:1999-05-01 00:00:00

  • Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.

    abstract::In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701279

    authors: Jerjis S,Roovers E,Muus P,Schaap N,de Witte T

    更新日期:1998-07-01 00:00:00

  • Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors.

    abstract::Umbilical cord blood (UCB) has increased access to hematopoietic cell transplantation (HCT) for patients without HLA-matched sibling donors (MSD). We compared outcomes of HCT using MSD (N=38) or UCB (N=60) among older patients (age ≥ 55 years) with AML or myelodysplastic syndromes (MDS). All patients received a reduce...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.114

    authors: Majhail NS,Brunstein CG,Shanley R,Sandhu K,McClune B,Oran B,Warlick ED,Wagner JE,Weisdorf DJ

    更新日期:2012-04-01 00:00:00

  • CD34+ cell dose, conditioning regimen and prior chemotherapy: factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation.

    abstract::The aim of this study was to define factors that significantly influence the early kinetics of donor chimerism after transplantation. In a retrospective study, the percentage of donor chimerism in peripheral blood measured with sex-chromosome-specific probes and fluorescence-in situ hybridization was analyzed in 184 r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704710

    authors: Mohr B,Koch R,Thiede C,Kroschinsky F,Ehninger G,Bornhäuser M

    更新日期:2004-12-01 00:00:00

  • Multicentre European study comparing selection techniques for the isolation of CD34+ cells.

    abstract::Primitive haemopoietic cells are required for studies in both the clinical and research fields and a number of systems have been developed to facilitate isolation of these haemopoietic cell populations. We have analysed the results from several European centres using positive selection of CD34+ cells from haemopoietic...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1701789

    authors: de Wynter EA,Ryder D,Lanza F,Nadali G,Johnsen H,Denning-Kendall P,Thing-Mortensen B,Silvestri F,Testa NG

    更新日期:1999-06-01 00:00:00

  • Short-term sonic-hedgehog gene therapy to mitigate myelosuppression in highly irradiated monkeys: hype or reality?

    abstract::The protection of hematopoietic stem and progenitor cells and their environment is required for recovery from radiation-induced (RI) myelosuppression. To achieve this goal, we propose a new gene therapy strategy based on local and short-term synthesis and expression of Sonic hedgehog morphogene (Shh) at the niche leve...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.162

    authors: Drouet M,Garrigou P,Peinnequin A,Hérodin F

    更新日期:2014-02-01 00:00:00

  • Toxoplasma retinitis/encephalitis 9 months after allogeneic bone marrow transplantation.

    abstract::In a 34-year-old patient toxoplasma retinitis/encephalitis developed 9 months after bone marrow transplantation. The BMT was complicated with a serious GVHD. Although she initially responded well to antibiotic therapy she died 2 years after BMT due to progressive infection. ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701128

    authors: Brinkman K,Debast S,Sauerwein R,Ooyman F,Hiel J,Raemaekers J

    更新日期:1998-03-01 00:00:00

  • 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study.

    abstract::This prospective pilot study aimed to evaluate the predictive value of (18)F-FDG PET/CT for early diagnosis of acute gastrointestinal GVHD (GI-GVHD). In all, 42 consecutive patients who received allo-SCT were included. (18)F-FDG PET/CT was systematically performed at a median of 28 (range, 24-38) days after allo-SCT. ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.144

    authors: Bodet-Milin C,Lacombe M,Malard F,Lestang E,Cahu X,Chevallier P,Guillaume T,Delaunay J,Brissot E,Moreau P,Kraeber-Bodere F,Mohty M

    更新日期:2014-01-01 00:00:00

  • Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation.

    abstract::Bloodstream infection (BSI) is a significant complication following allogeneic hematopoietic stem cell transplantation (allo-SCT). Corticosteroids mask inflammatory responses, delaying the initiation of antibiotics. We reviewed medical records of 69 allo-SCT patients who had been on >0.5 mg/kg prednisolone to investig...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704830

    authors: Chizuka A,Kami M,Kanda Y,Murashige N,Kishi Y,Hamaki T,Kim SW,Hori A,Kojima R,Mori SI,Tanosaki R,Gomi H,Takaue Y

    更新日期:2005-03-01 00:00:00

  • A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.

    abstract::Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. The killing of leukemia cells is proportional to the radiation absorbed dose. We studied the feasibility and toxicity of escalating the doses o...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1702230

    authors: Sobecks RM,Daugherty CK,Hallahan DE,Laport GF,Wagner ND,Larson RA

    更新日期:2000-04-01 00:00:00

  • A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies.

    abstract::Non-remitting patients with hematologic myeloid malignancies have poor prognosis. To overcome this problem, we investigated the use of reduced-intensity preconditioning umbilical cord blood transplantation (RICBT) combined with recombinant G-CSF (rG-CSF) with high-dose Ara-C, fludarabine, melphalan, and 4 Gy of TBI in...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2014.66

    authors: Gotoh M,Yoshizawa S,Katagiri S,Suguro T,Asano M,Kitahara T,Akahane D,Okabe S,Tauchi T,Ito Y,Ohyashiki K

    更新日期:2014-07-01 00:00:00